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Abstract
This invited review covers research areas of central importance for orthopaedic and maxillofacial bone tissue repair, including normal
fracture healing and healing problems, biomaterial scaffolds for tissue engineering, mesenchymal and foetal stem cells, effects of sex
steroids on mesenchymal stem cells, use of platelet-rich plasma for tissue repair, osteogenesis and its molecular markers. A variety of
cells in addition to stem cells, as well as advances in materials science to meet specific requirements for bone and soft tissue regener-
ation by addition of bioactive molecules, are discussed.
Keywords: bone regeneration • stem cells • biomaterials • polymers • regenerative medicine
Introduction
New approaches to clinical problems based on translational med-
icine start with basic research and progress ‘hand-in-hand’ with
clinical observations. Scientists are increasingly aware that this
‘bench-to-bedside’ approach to translational research is really a
two-way street which can strengthen and accelerate critical points
of the research process.
Bone defects due to trauma and to pathological and physio-
logical bone resorption represent a major challenge and are a
global health problem. The need for bone regeneration in cranial,
oral and maxillo-facial and orthopaedic surgery is one of the 
central clinical issues in regenerative and rehabilitation medicine.
It is difficult to convey the enormous social and psychological
handicap of persons with bone defects and the significant reduc-
tion in their quality of life. In addition to trauma, bone healing
problems may be related to age, sex and infection as exemplified
by diagnoses such as osteoporosis, osteopenia and severe 
dental problems related to loss of teeth. The aim of this review is
to describe the current state of the art in our understanding of
bone healing and bone regeneration.
Bone fracture healing and healing
problems
Bone repair after fracture is a special process where sequential
cellular and molecular events take place to generate new bone,
rather than a fibrous scar like other connective tissues. The pre-
cise series of ordered events required to produce new bone are
modulated by systemic and local factors, and disruption of these
orderly events may cause healing problems. Thus, a clear under-
standing of the sequence of events and their regulation is needed
to decide when and how an intervention is required to promote
healing and to avoid complications.
Since early histological descriptions of fracture healing in man
[1], the general pattern of indirect fracture healing, based on endo-
chondral ossification, has included the chronological phases of
haematoma, inflammation, angiogenesis, chondrogenesis to
osteogenesis and finally bone remodelling [2]. Direct healing
based on membranous ossification, with no periosteal reaction or
visible callus formation, is seldom seen. The well-established
characteristics of the above mentioned phases require different
processes of cell migration and differentiation, extracellular matrix
formation and organization towards calcification, as well as both
local and systemic modulation. Apart from the classical histologi-
cal phases of fracture healing, much remains to be understood
about the regulation of these processes both at the molecular and
the cellular level.
Formation of a haematoma related to blood vessel damage 
is accompanied by an inflammatory response [3], where pro-
inflammatory cytokines such as interleukin-1 (IL-1), IL-6, and 
particularly tumour necrosis factor-, initiate the bone healing
cascade and push it towards endochondral bone formation and
remodelling [4]. Secondarily, apart from ischemia, growth and 
differentiation factors and particularly the transforming growth
factor- (TGF-) superfamily, including bone morphogenetic 
protein (BMPs), as well as platelet-derived growth factors (PDGF),
fibroblast growth factors (FGFs) and insulin-like growth factors
(IGFs), orchestrate crucial events for chondro-osteogenesis,
including chemotaxis, mesenchymal and osteoprogenitor cell pro-
liferation and differentiation, and extracellular matrix ossification
[5]. Finally, angiogenesis, a key aspect of fracture healing, is also
regulated at the molecular level. An angiopoietin pathway has been
described in the early stages of the healing process [6], as has a
vascular endothelial growth factor (VEGF)-dependent pathway
related to endochondral bone formation, where BMPs stimulate
the expression of VEGF by osteoblasts and osteoblast-like cells
[7]. Inhibitory molecules are also needed to control growth factors
(GFs), and various BMP antagonists [8] are released into the
extracellular compartment (noggin, sclerostatin, follistatin, etc.).
Other inhibitory mechanisms include receptor inhibition of some
members of the TGF- superfamily that has been related to a
pseudo-receptor defined as BAMBI (BMP and activin membrane
bound inhibitor) [9], and intracellular inhibition by the activation of
I-Smads [10, 11], among other mechanisms. Many aspects of this
bone healing cascade of molecules, cells and events have been
identified, but the complex interactions and processes are still
only partially understood.
Interestingly, adult bone healing reproduces normal develop-
ment during embryogenesis, except for the associated inflamma-
tion, despite the limited number of osteoprogenitor cells available
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in the adult, and the strong influence of external and internal
mechanics. This fact offers researchers an invaluable clue towards
biological events in the developmental processes of skeletogene-
sis [12]. Bone formation during embryogenesis is initiated by
mesenchymal stem cells (MSC) aggregation and condensation,
which then progresses to endochondral ossification through car-
tilage formation, or to membranous ossification through
osteoblast differentiation. Although MSC are scarce in adult bone,
both committed osteoprogenitor cells from the periostium and
undifferentiated multipotent MSC from bone marrow are involved
in callus formation, which is important in the structural progress
of fracture healing. In addition to the classical triad of bone heal-
ing (cells, extracellular matrix and osteoinductive factors), a fourth
major factor (the biomechanical properties of the callus) has been
stressed recently [13, 14]. Mechanical influences on biological
processes, known as mechanobiology, significantly affect all
phases of bone formation. Not only may major external forces dis-
rupt the healing process, but mechanical loading influences on
endochondral ossification are also important as compression
enhances bone apposition [13], empirically defined since the 19th
century as Wolff’s law. However, earlier phases of osteogenesis
show increased cell proliferation if cyclic motion with associated
shear stresses occurs, although intramembranous ossification
may be permitted in areas with low stress and strain. Mechanical
signalling at the cellular level may modulate molecular changes in
cytoskeleton, integrins and ion channel activities with conse-
quences to the differentiation and gene expression of cells
involved in the healing process. Transduction mechanisms range
from direct mechanical stimulation of cells [15, 16], to fluid shear
stresses and various matrix effects that indirectly affect cells [17].
Many of these experimental studies were developed after clinical
studies showed the beneficial influence of interfragmentary
motion (of about 0.6 mm) in the early stages of the healing
process [18], and the role of mechanical stimulus in general as an
influence on the rate of healing.
Despite this well developed natural mechanism of fracture
healing, alteration of local and systemic factors may lead to
impaired healing. Non-union (or pseudoarthrosis), due to the false
articulation generated in the area of the unhealed fracture, and
delayed union, are the main problems in bone repair and are 
significant health care issues. Systemic factors such as use of non-
steroidal anti-inflammatory drugs (which inhibit cyclooxygenase
and therefore prostaglandins required in the inflammation phase),
age (with decreased expression of mediators, hormonal changes,
impaired osteoblast function), or smoking [19], and local factors
both influence fracture healing. Mechanical stability is required for
callus formation, and surgical techniques focusing on stability
greatly improve the chances of fracture healing, as excess motion
impairs it. Angiogenesis and appropriate tissue differentiation, key
factors required for callus formation, are also improved with 
fracture stability [20]. However, the rate of differentiation of osteo-
progenitors is modulated by the mechanical environment, thus
osteogenic differentiation may be promoted or impaired by move-
ment. When tensile strains occur in the interfragmentary gap, they
lead to ‘cleavage’ of the callus, and hydrostatic pressure and 
tensile strain at the ends of both fracture fragments may cause
fibrocartilage formation, leading to pseudoarthrosis instead of
bone healing, as modelled by Loboa et al. [21]. Despite all the
advances in surgical treatment of fractures, the management of
these healing problems is a challenge that would benefit signifi-
cantly from a deeper knowledge of normal bone healing and the
potential therapeutics derived from this knowledge.
Biomaterial scaffolds and tissue 
engineering in bone formation
Rebuilding human anatomy has long been the goal of reconstruc-
tive medicine. Currently, various strategies are in use to stimulate
healing of bone defects. Despite the fact that material science
technology has resulted in clear improvements in the field of bone
regeneration, no material fulfilling all requirements of a bone sub-
stitute has been developed, and dealing with large bone defects/
injuries still represents a major challenge.
Tissue engineering has emerged as an interdisciplinary field
with tremendous potential to develop and use new knowledge-
based materials that can be used in the fast-growing market of
advanced regenerative medicine and dentistry. In this context 
biomaterials play a crucial role in the development of tissue-
engineered organs. Degradable biomaterials can be used to fabri-
cate a scaffold which is well vascularized, integrated with the host
skeleton to place cells in close proximity with each other, and to
stimulate the formation of new living bone, connected to the
body’s biological systems. The fabrication of materials to provide
appropriate scaffolding conducive to cell adhesion and mainte-
nance of cell function is crucial.
Innovation in the structures of polymers, cell adaptation and
the mechanics of fundamental molecular biology offer the possi-
bility of developing biodegradable substances that may be injected
or shaped in tissues that will allow restoration of form and func-
tion while the added material will disappear through programmed
decomposition. By controlling the hydrophilicity and the surface
nano/microstructure, the degradable polymers can be good candi-
dates as scaffolds in tissue engineering and it may also be possible
to encourage and optimize the growth of cells within the artificial
structure. Thus cell-biomaterial based bone tissue engineering is
a promising concept for reconstruction/regeneration of bone
defects. However, much work remains before this approach can be
routinely applied in the clinical setting.
Bone is one of the hardest tissues of the human body and is
the main constituent of the skeleton; it supports fleshy structures,
protects vital organs such as those contained in the cranial and
thoracic cavities and contains the bone marrow, where the blood
cells are formed. Furthermore, bones form a system of levers that
multiply the forces generated during skeletal muscle contraction,
transforming them into bodily movements such as walking and
chewing. Bone is also highly vascularized and serves as a mineral
reservoir for homeostasis of the calcium blood level [22].
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Bone tissue develops either by intramembranous or endochon-
dral ossification and the embryonic development starts as early as
the fourth to sixth week. Membranous or direct ossification occurs
in parts of the skull or craniofacial skeleton, clavicles and scapu-
lae when mesenchymal cells proliferate and gradually change their
shape, which occurs within a layer of connective tissue.
Endochondral or indirect ossification takes place within a cartilagi-
nous model in the long bones and the rest of the skeleton, which
in addition to the growth of the length also increase in width via
appositional bone growth. This cartilage model is gradually
destroyed and replaced by bone formed by incoming cells from
adjacent periosteal connective tissues. In both processes the bone
tissue appears first as primary or immature tissue and grows 
rapidly from the first postnatal year to the end of adolescence. In
the adult skeleton bone tissue is either arranged in a trabecular
pattern or in a compact pattern [23]. A tentative third mode of
bone formation has been described in distraction osteogenesis
studies. Transchondroid ossification produces bone via chondroid
bone. It is speculated that hypertrophic and/or early stage chon-
drocytes undergo differentiation into osteoblast-like cells, which
lay done bone without capillary invasion.
As the development of bone is very complicated, birth bone
defects can occur in any bone although the bones of the skull and
face, spine, hips, legs and feet are affected most often resulting in
abnormal appearance and function [24]. The most common
defects of the skull and face are cleft lip, cleft palate and jaw defor-
mities. Most of these defects can be repaired surgically. Often, the
surgery is complex and involves reconstructing deformed or
absent body parts [25–27].
Bone defects due to trauma, and to pathological and physiolog-
ical bone resorption still represent a major challenge. The need for
bone regeneration in cranial, oral maxillo-facial and orthopaedic
surgery is a major clinical issue. Most fractures heal well using
standard treatments, mostly without any scar tissue formation.
However, bone defects due to tumour resections, unhealed frac-
tures, major trauma and bone resorption of edentulous jaws or of
tooth-supporting alveolar bone are candidates for bone recon-
struction and cause significant handicap without adequate treat-
ment. In neurosurgery, spinal fusion is performed in many
patients suffering from intervertebral disc degeneration, and this
procedure also requires bone grafting.
Plastic and reconstructive surgeons conventionally fill and
repair bony defects using autologous bone transplantation as the
gold standard [28]. Current clinical treatments to repair bony
defects can be problematic and often yield poor healing due to the
anatomy and physiology of bone tissue, as well as the limitations
of knowledge of the process. Because of the major problems asso-
ciated with autograft transplantation, such as insufficient tissue,
donor-site injury and surgical risks as such as bleeding, infection
and chronic pain, alternative approaches are needed. Skeletal
defects may require volumes of bone often not available. The donor
site for bone harvesting is usually the iliac crest, which requires a
second surgical intervention and has some surgical morbidity.
Allografts can be used, especially in prosthetic reconstruction, but
may still not solve many problems of bone deficiency.
Because of the disadvantages associated with both autografts
and allografts, scientists have long searched for biocompatible
materials that could be substituted for the transplanted bone.
Although most of the available synthetic bone substitutes have
some of the positive properties of an autograft, to date no single
synthetic material offers all the benefits of the patient’s own bone.
For instance, calcium phosphate bioceramics do not possess 
sufficient osteogenic properties to allow reconstruction of large
defects [29, 30]. Thus despite the commercial availability of many
bone substitute materials for clinical application, the use of 
alloplastic materials and autologous bone grafting remains the
preferred approach to treatment of bone defects [31]. Thus, in
bone tissue engineering, it may be of importance to primarily
specify the area and the function for regeneration or implantation
of bone. In those cases, orthopaedics, neurosurgery and maxillo-
facial surgery and implant dentistry may have different treatment
modalities and may ask for materials to be used either in a solid
or an injectable phase for the different targets.
Bone tissue engineering
In view of the above limitations and the increasing demand for
bone grafting procedures, surgeons are looking for a better
approach. Tissue engineering combines bone marrow cells or
MSC, synthetic scaffolds and molecular signals (growth or differ-
entiating factors) to form hybrid constructs. In a classical
approach, bone tissue engineering consists of harvesting bone
marrow from a patient, isolating MSC by adherence to tissue cul-
ture plastic, expanding and differentiating MSC in culture and then
seeding them onto a suitable synthetic scaffold prior to implanta-
tion into the same patient [32]. It has been shown that from a
small volume (0.1–3 ml) aspirate, alveolar bone marrow stromal
cells (BMSC) expand by 70% [33].
Although this raises few ethical issues, harvesting of cells from
bone marrow is still an invasive procedure, and in addition stem
cell numbers may decrease significantly with the age of the 
individual. The search for more readily accessible sources of
pluripotent cells has led to investigation of other tissues, including
mobilized peripheral blood, umbilical cord blood and more
recently, periodontal ligament and deciduous and permanent
teeth. Dental pulp tissue is also a readily accessible source of
pulp-derived MSC (PDSC) and can be easily isolated. PDSC
express the endothelial and smooth muscle marker STRO-1 [34]
and display a pericyte phenotype, with expression of the pericyte-
associated antigen 3G5 [34]. It is therefore assumed, but not 
confirmed, that the perivascular region in the pulp is the niche for
PDSC and that pericytes give rise to dental pulp stem cells.
Isolated dental pulp stem cells have been shown to be plastic-
adherent and express the MSC markers STRO-1, CD90, CD29,
CD44, CD166, CD105, CD106, CD146, CD13 and are also negative
for CD14 and CD34 [35, 36]. In vitro, PDSC are capable of self-
renewal, display plasticity and mutilineage potential (adipocytes,
chondrocytes, osteoblasts, neural cell progenitors and myotubes)
and can therefore be defined as stem cells [37].
722 © 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
To date, these approaches have been evaluated in both animal
experiments and clinical studies involving low numbers of
patients, with inconclusive outcome and low bone regeneration
efficacy [38–40]. Overall, the clinical outcome have been disap-
pointing, especially with respect to restoration of large bone
defects. The limited success of clinical studies to date may be
attributable to a number of issues, related primarily to translation
of laboratory procedures to clinical application. Translation of 
laboratory processes into clinically effective, reproducible, safe,
economically viable and competitive products is generally
acknowledged to be a complicated and challenging phase in the
development of new clinical techniques [32]. In the context of bone
tissue engineering, the difficulties reflect the multidisciplinary
nature of the concept.
Biomaterial scaffolds
Bone tissue engineering utilizes scaffolds to deliver biofactors
including cells, genes and proteins to generate bone and assess-
ment of blood vessel formation and maturation into the construct.
The scaffold itself must fulfil three primary functions to ensure suc-
cessful treatment of bone defects. First, the scaffold must provide
the correct anatomic geometry to define and maintain the space for
tissue regeneration. Second, the scaffold must provide temporary
mechanical load bearing within the tissue defect and third, the 
scaffold should enhance the regenerative capability of the chosen
biofactor; a balance to a regenerative capacity. For load-bearing 
purposes, achieving stiffness and strength equivalent to bone tissue
requires minimally porous scaffolds. Conversely, enhanced delivery
of biofactors requires more highly connected porous scaffolds to
allow cell migration, vascularization and connective tissue formation
within scaffolds. In clinical applications, it is obvious that scaffolds,
matching complex anatomic defects require computational methods
and control of anatomic shape and architecture.
Many different materials have been proposed as synthetic bone
substitutes. Hydroxyapatite (HA), Ca10(PO4)6(OH)2, is regarded as
one of the most bioactive bone substitute ceramics because of its
superior osteoconductivity. This applies to HA of synthetic or 
biological origin, -tricalcium phosphate (-TCP) and biphasic
calcium phosphate. Calcium phosphate biomaterials are currently
used, for example, for bone repair, substitution, augmentation and
regeneration. As synthetic bone substitutes, the main advantages
of the ceramics are excellent biocompatibility and better stability
than polymers and metals in the living body. Synthetic octacalcium
phosphate has been shown to be a good precursor of biological
apatite in bone and tooth and has shown better bone regenerative
and biodegradable characteristics than other calcium phosphate
bone substitute materials [41]. A disadvantage is that it is some-
times difficult to achieve close apposition of the material to the
surrounding bone, especially in complicated defects and this is
essential for complete and successful bone regeneration. Another
general disadvantage of the ceramics is inherent brittleness. This
can be overcome by blending ceramics with, for example, poly-
esters to form a composite that combines the mechanical strength
and osteoconductivity of calcium phosphates with the high affinity
for cells and good biodegradability of polyesters.
Development of composite materials which consist of a
biodegradable matrix incorporating bioactive rigid particles com-
bines the reinforcement activity provided by HA-based particles
with the tailored degradation kinetics of resorbable polymers [42].
Many studies have examined the use of bioceramic particles such
as silica, HA or other calcium phosphates in combination with
biodegradable polymers (i.e. poly(ε-caprolactone) [PCL], poly(lac-
tide) [PLA]) to produce bone substitutes (Fig. 1).
The positive results of studies using these systems might be
attributable to structural similarity to the mineral phase of bone,
and osteoconductive and bone-binding properties [43–45]. For
example, compared to PCL scaffolds, composite scaffolds con-
taining PCL and TCP, designed for load-bearing applications,
exhibit improved hydrophilicity, compressive modulus and
strength. Human alveolar osteoblasts, grown on the composite,
exhibit higher seeding efficiency, better proliferation and earlier
expression of bone matrix related proteins than cells grown on
PCL [46]. The addition of calcium phosphate particles to this sys-
tem generates needle-like, Ca-deficient HA crystals, which
improves the compressive strength of the construct. This material
thus meets many of the major requirements of scaffolding mate-
rial for bone-tissue engineering [47].
Mechanical properties can also be improved by cross-linking.
For example, the mechanical properties of cross-linked
poly(propylene fumarate) (Fig. 2) and CaSO4/-TCP) composite are
similar to those of cancellous bone substitutes, with compressive
Fig. 1 Molecular structure of (A) PLA and (B) PLC.
Fig. 2 Molecular structure of poly(propylene fumarate).
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strengths of 5 MPa and a compressive modulus of 50 MPa during
degradation [48]. Composite bone substitutes are also available in
injectable form, an obvious advantage in the clinical setting. For
example, HA-atelocollagen composites have proved suitable pre-
cursors for osseous regeneration [49]. However, despite many
positive outcome, the results of most studies to date show that the
incorporation of a ceramic phase improves bioactivity, but the
mechanical properties of the composites are inadequate [50].
Another observed disadvantage is that the HA particles within a
PCL matrix tend to migrate to the surface and form clusters, cre-
ating inhomogeneous scaffolds [51].
Another fundamental component of bone tissue engineering
is the addition of GFs. BMP-2, a member of a class of proteins
and TGF-s are regarded as the most important regulators of
bone repair and regeneration. Addition of GFs to the scaffolds is
intended to create an osteogenic microenvironment and various
strategies are commonly used for controlled delivery of GFs,
such as hydrogels, direct loading, electrostatic interaction and
covalent binding.
Synthetic scaffolds
There are a wide variety of synthetic polymers that have been
investigated for biomaterial and tissue engineering applications.
Scaffolds comprised solely of degradable polymers have also
been successfully used to aid bone regeneration in vivo [52]. The
biggest advantage of polymers is that properties such as
hydrophilicity, degradation rate and mechanical properties can be
optimized. These properties can be manipulated in various ways,
most commonly by copolymerization or the introduction of differ-
ent architecture. Control of the rate and extent of degradability 
of a polymeric biomaterial is critical. Many factors influence
degradability, such as chemical structure, copolymer composition,
architecture, molecular weight, morphology, surface area and
medium character.
Among the various families of degradable polymers, aliphatic
polyesters are prominent, because hydrolytic and/or enzymatic
chain cleavage yields -hydroxyacids. Aliphatic polyesters can be
synthesized through either polycondensation of functional acids
and alcohols, or ring-opening polymerization of cyclic esters.
PLLA belongs to the group of poly(-hydroxy acids) but PLLA is
of limited application because it is hydrophobic, with no reactive-
chain group. It is difficult to chemically attach active molecules
like drugs and recognition agents onto these and other polyesters:
the high hydrophobicity sometimes interferes with the intended
medical application.
A scaffold made of resorbable material is intended primarily
as a temporary support during the regeneration phase. Ideally,
once the damaged tissue has been sufficiently regenerated, the
scaffolding should start to degrade and lose its mechanical
properties. The material needs good mechanical properties to
be able to withstand complex forces and for this reason crys-
talline materials are often used. A potential disadvantage of
crystalline materials is the risk of unfavourable tissue
responses: amorphous polymers are preferable, but their
mechanical properties may be inadequate.
In this context, biodegradable block copolymers show promise
as biomaterials because their amphiphilic behaviour, mechanical
and physical properties can be manipulated by adjusting the ratio
of the constituting block or adding new blocks of desired proper-
ties. Research in this area dates back many years and there are
numerous publications about the properties of block copolymers.
Poly(lactide-co-glycolide) has shown good results in several
research studies; however, its clinical utility is limited due to its
relatively poor mechanical properties. Copolymerization of PLLA
and poly (ethylene glycol) offers several means of modifying the
properties to optimize them for medical application. It has been
shown that adjusting the block lengths of both components can
modulate the crystallinity and that hydrophilicity is better that that
of PLA homopolymers [53]. Another interesting system is copoly-
merization with dioxanone. Poly(1,5-dioxepan-2-one) (Fig. 3) is an
amorphous polymer: the soft, amorphous phase provides elastic-
ity and desirable degradation characteristics, whereas copolymer-
ization with lactide gives a rigid crystalline phase, which acts as a
physical cross-linker and therefore improves the mechanical prop-
erties. It has also been shown that the hydrophilicity of the poly-
mer changes when different monomer compositions are used [54,
55]. In a series of experiments using poly(1,5-dioxepan-2-one)
(DXO)-containing polymers different in vitro cell culture systems
have indicated that these polymers are promising as scaffolds for
bone tissue engineering [56–59].
Copolymerization can also be used to solve one of disadvan-
tages of many aliphatic polyesters, i.e. the absence of reactive
sites. Multiple sites that allow selective attachment of substances
such as bioactive molecules have been synthesized by copolymer-
ization [60]. Synthetic bone substitutes, composite grafts and
polymers all have enormous potential and optimal results can be
achieved by careful design.
Micro- and nanostructural properties 
of scaffolds
Besides the choice of appropriate composition, both micro- and
nanostructural properties of the scaffolding materials are of
utmost importance. Surface properties, both chemical and topo-
graphical, significantly affect the potential for cellular adhesion
and proliferation, determining not only cell survival, signalling,
growth and reorganization but also cellular phenotype and gene
expression profile. Moreover, scaffolds must have open pores that
Fig. 3 Molecular structure of poly(1,5-dioxepan-2-one) (DXO).
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allow cell in-growth and even cell distribution throughout the
porous structure. The porosity should also facilitate neovascular-
ization from the surrounding host tissue. Furthermore, the 
scaffolds should have adequate microporosity in order to allow
capillary in-growth. However, the degree of porosity influences
other important properties of the scaffolds such as degradation
characteristics and mechanical stability, which need to be consid-
ered in the context of the mechanical demands of the particular
tissue to be replaced.
Conclusion
Despite major advances in material science technology, a material
fulfilling all requirements of a bone and cartilage substitute has yet
to be developed. For the repair of bone defects, tissue engineering
should combine cells capable of osteogenic activity with an appro-
priate scaffolding material, in order to stimulate physiological
bone regeneration and repair processes.
MSC derived from bone marrow are multipotential: depending
on culture conditions, such cells have the potential to differentiate
into many different cell types, including osteoblasts and chondro-
cytes. Thus, MSC comprise a readily available and abundant
source of cells for tissue engineering applications. The lack of
immunogenicity of MSC has opened up the potential of using
these cells in tissue repair.
The goal of these strategies is to exploit the body’s natural abil-
ity to repair injured bone with new bone cells, and to remodel the
new bone tissue in response to local stress factors. The primary
function of an optimal biomaterial scaffold is to support the area
undergoing reconstruction, providing adequate initial mechanical
strength. It should also stimulate new bone formation in the
region, and then gradually degrade without causing a pronounced
inflammatory response, thus allowing the new bone to remodel
and assume the mechanical support function.
Selection of the most appropriate scaffolding material is crucial
in a tissue-engineered construct. Preferable to ceramics are
biodegradable scaffolds based on polyesters and hydrogels, which
can be chemically modified with a controlled degradation time and
readily processed into three dimensional, porous structures, with
desired pore morphology. Tissue engineering has thus emerged
as an interdisciplinary field with tremendous potential to develop
and apply new, knowledge-based materials in advanced regenera-
tive medicine and dentistry. In this context, biomaterials play a
crucial role in the development of tissue-engineered organs.
Degradable biomaterials can be used to fabricate a three-
dimensional construct or scaffold which is well vascularized, inte-
grated with the host skeleton to maintain cells in close proximity
to one another, and to stimulate the formation of new living bone, 
functioning as part of the body’s biological systems. Thus the 
fabrication of materials which provide appropriate scaffolding
conducive to cell adhesion and maintenance of cell function is of
fundamental importance to successful bone regeneration.
To fulfil the prerequisites of biocompatibility, as well as to meet
the increasing demands of functional and tailor-made surfaces of
the future, much research effort is focused on surface modifica-
tion, especially the design and development of functional and
nano-structured surfaces. Whenever a polymeric biomaterial is
used, the surface chemistry and structure are of fundamental
importance, especially in the early stages after implantation.
Biological interactions between the device and the host tissue
occur mainly on the surface of the scaffold. For this reason, there
is a strong demand for viable techniques for covalent surface
modification of polymers, in order to enhance surface wettability
and thus circumvent an important limitation of current polymeric
biomaterials: their hydrophobicity. Surface modification also
offers the potential to functionalize the surface, so that bioactive
moieties may be attached and the biocompatibility improved.
Depending on the nature of the substrate, there are several different
techniques by which the surfaces of both synthetic and natural
materials can be covalently modified.
Mesenchymal stem cells 
and osteogenesis
Bone tissue
Bone tissue is composed of bone matrix and bone cells. Bone
matrix is primarily built of type I collagen (90%), with the remain-
ing 10% being composed of a large number of non-collagenous
proteins (e.g. osteocalcin [OC], osteonectin, bone sialoproteins
and various proteoglycans). Non-collagenous proteins participate
in the process of matrix maturation, mineralization and may regu-
late the functional activity of bone cells. Two main types of bone
cells have been identified. Osteoblasts (bone-forming cells) and
osteoclasts (bone resorbing cells) that together with their precur-
sor cells and associated cells (e.g. endothelial cells, nerve cells)
are organized in specialized units called bone multicellular units
(analogous to the organization of kidney cells into nephrons) [61].
The main function of the bone multicellular units in the adult skele-
ton is to mediate a bone ‘rejuvenation’ mechanism called ‘bone
remodelling’ aimed at the maintenance of the integrity of the skele-
ton by removing old bone of high mineral density and high preva-
lence of fatigue micro-fractures through repetitive cycles of bone
resorption and bone formation [61, 62]. During bone formation
phase, the osteoblasts are recruited from MSC present in bone
marrow [63]. On the other hand, osteoclasts are derived from
haematopoietic stem cells through committed osteoclast progen-
itors that fuse to form mature multinucleated cells [64].
Understanding the mechanisms that control the differentiation of
osteoblastic cells from MSC is thus of one of the fundamental
areas of research of bone biology. The ability of MSC to differenti-
ate into non-osteoblastic cells has been recognized recently and
here we attempt to provide an update regarding the trans-differen-
tiation potential of MSC with regard to the relationship between
osteoblast and adipocyte differentiation.
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Origin of osteoblasts
One current dogma of bone biology is that mature osteoblasts are
differentiated from precursor cells present in the bone marrow.
Based on the pioneer work of Friedenstein and coworkers [65, 66],
it has been recognized that the non-hematopoietic compartment
of bone marrow (known as bone marrow stroma) contains a
group of fibroblast-like stem cells with osteogenic differentiation
potential [referred to as MSC, bone marrow stromal cells (BMSC),
or skeletal stem cells]. The exact location of these cells in vivo
is not known but recent work suggests that MSC are located in 
the perivascular spaces as sub-endothelial cells surrounding the
vascular sinusoids in the bone marrow [67].
Isolation and characterization of bone marrow
derived MSC
MSC have been isolated from the low-density mononuclear
fraction of bone marrow aspirates by their selective capacity
for adherence to plastic surfaces compared to haematopoietic
cells [68–71]. However, MSC cultures established by this
method are heterogeneous and contain both stem cells and
progenitor cell populations. This has been demonstrated by
clonal analysis of MSC where ~30% of the clones represented
true stem cells [72, 73]. Stemness of MSC is defined as the
ability of the clonal cells to form ectopic bone and bone mar-
row organ upon in vivo implantation with an osteo-conductive
carrier such as HA/TCP in immune deficient SCID mice [74].
Thus, describing the whole plastic-adherent MSC population as
‘stem cells’ is not appropriate.
The human MSC (hMSC) phenotype has been defined through
expression of many CD markers. hMSC are negative for
haematopoietic surface markers (CD34, CD45, CD14) and positive
for STRO-1, CD29, CD73, CD90, CD105, CD106, CD166, CD146
and CD44 [74–76]. Several attempts have been made to isolate a
homogeneous population of the true stem cells among MSC
based on the expression of one or more of these specific surface
markers. STRO-1 alone or in combination with CD106 (VCAM-1)
or CD146 (MUC18) [77], CD271 (low-affinity nerve GF receptor)
[78], CD18 (2 integrin) [79] or the embryonic stem cell marker
SSEA-4 [80] have been tried. A global plasma membrane pro-
teomic signature has been established in order to identify novel
surface markers for ‘stemness’ [75]. However, there is still a need
to identify both sensitive and specific markers that allow prospec-
tive isolation of the true multipotent MSC population.
Interestingly, MSC with similar biological characteristics to
those derived from bone marrow have been isolated from other
sources including peripheral blood [81], umbilical cord blood
[82], synovial membrane [83], deciduous teeth [84] and amniotic
fluid [85]. These various MSC populations share some common
properties and surface phenotypes but differ in their differentiation
potential and their gene expression profile in ways that reflect their
tissue of origin [86].
In vitro differentiation of MSC into osteoblast 
lineage cells
MSC are capable of differentiation under appropriate in vitro con-
ditions to mesoderm-type cells, e.g. osteoblasts, adipocytes and
chondrocytes [74, 87]. Differentiation is induced through addition
of ‘cocktails’ of morphogens and chemicals important for differen-
tiation of a particular cell type. For example, for osteoblast differ-
entiation a mixture of dexamethasone, calcitriol, ascorbic acid and
-glycerophosphate is usually added. In vitro differentiation is
verified by demonstrating the induction of osteoblast-specific
gene expression and proteins. Similar procedures are used for
demonstrating differentiation to other cell types. For example, the
ability of hMSC to differentiate into adipocytes has been reported
by several investigators using a cocktail of dexamethasone,
isobutyl methyl xanthine, insulin and rosiglitazone (a peroxisome
proliferator-activated receptor 2 (PPAR-2) agonist) [71, 88, 89].
In vivo differentiation of MSC into bone
There is increasing recognition that in vitro osteoblast differentia-
tion assays have limitations and thus there is a need to verify
osteoblast differentiation potential of MSC based on an in vivo
assay. Friedenstein employed ‘diffusion chambers’ to determine
the differentiation potential of MSC [66]. Ectopic implantation of
MSC with a carrier (HA/TCP) in an open system (subcutaneous
implantation) in SCID mice has evolved as the ‘gold standard’
assay for osteoblast differentiation and stemness characteristics
of MSC [87, 90, 91]. Under these conditions, MSC can form bone
and a bone marrow microenvironment supporting haematopoesis,
whereas osteoprogenitor cells can only form bone [91]. This
assay has also been employed to demonstrate the ability of the
multipotential MSC cell to exhibit self-renewal and maintenance of
stemness capacity during serial implantations [92].
The importance of testing the in vivo phenotype of cultured
MSC is shown by the recent demonstration of the limited value of
standard in vitro criteria for identification of hMSC clones with in
vivo bone-forming capacity [93]. In this study, using DNA
microarray analysis, a predictive molecular signature was identi-
fied for in vivo bone formation of MSC that can be employed to
select for an MSC population with high in vivo osteogenic capac-
ity for bone regeneration [93].
Factors and pathways controlling osteoblast 
differentiation of hMSC
Several approaches have been employed in order to identify 
factors and pathways important for lineage-specific differentiation
of hMSC. Using a genetic approach, several lineage-specific 
transcription factors have been identified and demonstrated 
to induce MSC differentiation. For example, core-binding factor
1(CBFA1/Runx2; Runx  Runt-related factors) [94], osterix [95]
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(Osx) and lipoprotein related receptor 5 (Lrp5) [96] overexpres-
sion lead to osteoblast differentiation, whereas PPAR-2 [97] and
Sox9 [98] induce adipocyte or chondrocyte lineages, respectively.
Alternatively, a ‘micro-environmental’ approach has been
employed where MSC are exposed to different mixtures of GFs,
hormones and extracellular matrix components to induce their 
differentiation. These experiments identified several factors that
induce osteoblast differentiation, e.g. BMPs [99], Wnt [100] or
that inhibit osteoblast differentiation, e.g. Dlk1/Pref-1 [101] and
Noggin [102].
We have employed novel proteomic approaches to identify the
intracellular signalling pathways that determine the osteoblast 
differentiation fate of MSC [103]. A newly developed quantitative
proteomic method called stable isotope labelling in cell culture has
also been employed to compare the phosphotyrosine signalling
pathway initiated by epidermal growth factor (EGF) which resulted
in osteoblast differentiation, with that of PDGF which did not.
Interestingly, more than 90% of the signalling proteins were 
utilized by EGF and PDGF, whereas the phosphatidylinositol 
3-kinase (PI3K) pathway was exclusively activated by PDGF, impli-
cating PI3K as a possible control point. Indeed, chemical inhibition
of PI3K in PDGF-stimulated cells rescued the osteoblast differen-
tiation phenotype [103]. These studies demonstrate the ability of
state-of-the-art quantitative proteomic approaches to identify 
targets for pharmacological intervention in order to control MSC
differentiation.
Defining the relationship between osteoblast 
and adipocyte differentiation from MSC
Recent studies have suggested that bone mass and fat mass are
strongly associated processes mediated by the same hormonal
factors, including insulin [104], growth hormone [105] and
recently leptin [106].
The majority of clinical conditions associated with bone loss,
including aging, osteoporosis, anti-diabetic drugs (thiazolidine-
diones) treatment and increased cortisol production, are known to
be accompanied by increasing marrow adipocytes, due to a shift in
the differentiation decision of MSC to favour the adipocyte lineage
over the osteoblast lineage [107, 108]. Several lines of evidence
support this relationship between osteoblastogensis and adipoge-
nesis. At a cellular level, an inverse relationship and phenotypic
plasticity exists between osteoblast and adipocyte differentiation of
bone marrow MSC. Several transcriptional factors and pathways
have been demonstrated to control the balance between osteoblast
and adipocyte differentiation of MSC, for example, transcriptional
coactivator with PDZ-binding motif [109], PPAR-2 [110], FosB
[111], canonical Wnt--catenin and non-canonical Wnt signalling
pathways [112]. We have also reported that Wnt co-receptor, Lrp5
with active mutation (T253I) and Wnt activation control the differ-
entiation of hMSC into osteoblast versus adipocyte in patients with
high bone mass due to this mutation [96].
On the other hand, bone marrow adipocytes secret several
inflammatory factors, including leptin, adipsin, adiponectin and
resistin, that act in a paracrine manner to suppress osteoblast
function and differentiation [113, 114]. Very recently, Lee et al.
[115] provided the first evidence that bone can act as an endocrine
organ to regulate glucose and fat metabolism through the 
secretion of OC (osteoblast-specific protein), which acts as a pro-
hormone to decrease fat mass and promotes expression of
adiponectin, an insulin-sensitizing adipokine [115, 116]. This
novel finding established a cross-talk between bone formation and
energy metabolism through the secretion of systemic factors. In
this context, we have recently identified dlk1/FA1 protein (	 like
1/foetal antigen 1) as a novel pre-adipocyte derived factor that has
regulatory effects on both osteoblast and adipocyte differentiation
of hMSC [101]. dlk1/FA1 is an imprinted paternally expressed
gene that encodes for a trans-membrane protein. It has six EGF-
like repeats in its extracellular domain, which is similar to other
members of the Notch/Delta/Serrate family. Also, we showed that
the extracellular domain of the molecule FA1 which circulates in
blood and tissue fluids, acts in an endocrine fashion to control
bone and fat mass in vivo [117]. Using DNA microarray technol-
ogy, we found that dlk1/FA1 modulates the expression of several
pro-inflammatory cytokines by MSC and thus may influence
hMSC differentiation by controlling the composition of the
microenvironment ‘niche’ [118]. Thus, identifying novel secreted
factors that regulate osteoblast/adipocyte cross-talk is an 
important research area that can potentially lead to identification
of therapeutic targets for enhancing bone formation.
MSC and sex hormones
Sex hormones, especially oestrogens, have a critical role in devel-
opment and maintenance of healthy skeleton [119, 120], but it is
clear that sex steroids influence not only mature differentiated bone
cells, but also the behaviour of stem and different stage progenitor
cells [121]. The phytoestrogen genistein enhances osteogenesis
and represses adipogenic differentiation of hMSCs [122].
hMSC express oestrogen receptor (ER)- and possibly also
several ER- isoforms [122–125]. Interestingly, osteogenic 
differentiation seems to increase the mRNA expression of all ERs
present in MSC with the exception of ER-4 isoform that seems to
be mainly expressed in undifferentiated MSC [122]. Such changes
in ER profile during differentiation of MSC suggest different
effects of and sensitivity to oestrogens depending of the differen-
tiation lineage and stage. ER gene polymorphism may also
account to certain interindividual variablity in responses to 
estradiol stimulations [125].
17-estradiol enhances dose dependent osteogenesis from
hMSC as shown by up-regulation of OC and increased calcium
deposition [124]. In other work, where MSC from both male and
female donors were stimulated with estradiol and testosterone,
estradiol also increased calcium deposition, but alkaline phos-
phatase (ALP) activity increased only in cells isolated from male
donors [125]. Testosterone, on the other hand, had no effect on
calcium deposition in either sex. Resveratrol, a polyphenolic phy-
toestrogen, has been shown to enhance osteoblastic maturation of
J. Cell. Mol. Med. Vol 15, No 4, 2011
727© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
hMSC, possibly through extracellular signal-regulated kinase 1/2
(ERK1/2) pathway [126, 127].
More recent studies have revealed that hMSC can express 
several key enzymes needed for intracrine conversion of dehy-
droepiandrosterone to oestrogens or testosterone [122, 128,
129]. This suggests the interesting possibility that hMSC may
themselves in certain conditions make the needed sex hormones
or adjust their levels using serum dehydroepiandrosterone as a
precursor, and participate therefore in an intra-, auto- or paracrine
manner in their own differentiation processes and in overall more
complex local sex hormone regulation in bone [130].
Effect of aging on osteoblastogenesis
One of the most consistent histomorphometric findings in bone
biopsies obtained from elderly persons is the presence of
decreased mean wall thickness in both trabecular and cortical
bone indicating decreased osteoblastic bone-forming capacity
during bone remodelling [131]. Mean wall thickness is dependent
on both the number of recruited osteoblasts at the beginning of
bone formation phase and the activity of individual osteoblasts.
Recruitment of an adequate number of osteoblasts is dependent
on the availability of stem and precursor cells and their proper
response to growth, differentiation and chemotactic signals in the
bone microenvironment. Matrix production and mineralization
functions of mature osteoblasts are dependent on the proper
response of osteoblasts to hormones, GFs and cytokines as well
as the availability of nutrients and ions necessary for accomplishing
these processes. Age-related impairment of osteoblast functions
can thus be the result of any mechanism interfering with these
processes. It has been shown that the number of MSC does not
change with aging or in osteoporosis [132] and that MSC exhibit
a limited lifespan in vitro, with all the characteristics of the in vitro
replicative senescence phenotype [133]. Interestingly, an age-
related decline in the maximal lifespan of hMSC has been
observed, from 41 
 10 population doublings in young donors to
24 
 11 population doublings in old donors [133]. In addition to
impairment of cell proliferation of MSC with aging, it was also
shown that the senescent microenvironment affects MSC 
functions. As a surrogate condition for senescent microenviron-
ment experienced by hMSC, the effects of sera from young 
and old persons on MSC function were tested, and it was 
found that aged-sera inhibited osteoblast differentiation and 
functions of MSC [134]. Thus, intrinsic aging of MSC and the 
negative effects of the senescent microenvironment are possible
mechanisms for the observed defective osteoblast function and
bone formation in vivo in aged human beings. The senescent 
phenotype of MSC can be ‘rescued’ through overexpression of
human telomerase reverse transcriptase gene [135]. The 
telomerized hMSC exhibit enhanced cell proliferation and in vivo
bone formation capacity [135]. Telomerization also enhances gene
expression of some osteoblastic genes [136]. Other approaches to
rejuvenation of senescent MSC need to be explored for their
potential use in therapy.
Conclusion
During the last decade, enormous amounts of data have been
gathered related to the mechanisms of osteoblast differentiation
from stem cells. It is expected that this knowledge will be trans-
lated into novel approaches to enhance bone regeneration and
bone formation, a much needed task to manage the major health
care problem of bone fractures and osteoporosis.
Embryonic, foetal and adult stem cells
in osteogenesis
Cellular therapy is becoming a useful addition to medical therapies
for repairing, restoring or ameliorating function of tissues. Several
cell types and tissues have been proposed as starting material
including autologous cells, adult stem cells (including specific 
tissue populations and also bone marrow and adipose MSC),
embryonic stem cells, foetal cells and tissues from placental 
and amniotic fluid [137–143]. Some cell choices are more 
adaptable to cellular therapy in patients [144]. Tissue from 
animals and human beings at all stages of development must be
evaluated for the advantages and disadvantages of each cell type
(Fig. 4). The terminology of embryonic, foetal and adult stem cells
is complicated. Legally, the term ‘embryo’ denotes the earliest
stages following fertilization of an ovum by a sperm. Zygote would
include early stage cleavage embryos produced by cell division up
to 50–60 cell-stages (each cell of which is a blastomere) and the
blastocyte for the 60 cell stage to the point of implantation at
about 2 weeks after fertilization. Pathology would classify the
embryonic stage as up to 9 weeks of gestation and thereafter as
the foetal stage from 9 weeks to until birth. Different cell lines can
be established from each of these tissues, but with different com-
plications encountered in tissue culture techniques needed for
each. Embryonic stem cells are harvested from pre-implantation
embryos from the inner-cell mass before the first 2 weeks of
development. These cells are frequently obtained from extra
embryos developed by in vitro fertilization techniques to aid cou-
ples with fertility problems. There has been a moratorium on use
of embryonic stem cells since 1975 with new laws in 1993 permit-
ting use under certain circumstances. Because these particular
cells have created an ethical debate, other researchers have begun
using embryonic or foetal cells derived from voluntary interruption
of pregnancy between 5 and 8 weeks [145]. Cell lines are normally
developed from the genital ridge of the foetus but specific tissues
can be isolated from immature tissue with the necessity to add
GFs to assure particular cellular differentiation. Most foetal cell
research has developed from research using specific tissues at the
latter end of the first trimester (11–14 weeks) following voluntary
interruption of pregnancies. As this tissue (9 weeks) is consid-
ered an organ donation in most countries, it bypasses the major
problems that have been raised by embryonic stem cells. Cell lines
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at this stage are tissue specific and therefore cells are differenti-
ated and have specific functions [142, 146–148].
Cell-based therapies for bone
The first cell-based strategy used for repair of bone tissue was
autologous connective tissue progenitors harvested from the iliac
crest and immediately transplanted to sites for skeletal repair in
the same patient [149, 150]. This autograft procedure can be
accomplished without any outside manipulation of the tissue (i.e.
cell separation, culture or expansion) and is thus considered part
of a surgical procedure and is not regulated as a complex cell ther-
apy. If extensive manipulation has to be done, then the procedure
falls into a specific regulatory process which requires a certain
infrastructure for cell culture. Although the auto-grafting strategy
is used by many surgeons due to the ‘supplemental’ biological
activity and low risk involved with use of autologous bone marrow,
only a very small fraction of the cells actually survive and only 1
of 103 or 104 cells are potentially active [151]. The success of
marrow grafting is therefore entirely dependent on transfer of suf-
ficient numbers of progenitor cells, and therefore this approach
may be least applicable in those situations where it is most
needed, because ageing or disease are accompanied by a reduc-
tion of healthy marrow elements and especially osteogenic pro-
genitors. Alternative cell sources are therefore of great interest, in
particular normal allogeneic sources, which would provide ‘ready-
for-use’ products for bone repair strategies.
Fig. 4 Development stage, cell type and source of cells currently used in cellular therapy. Cellular source can come from human and animals at different
stages of development including embryonic, embryonic-foetal, foetal and adult involving different beginning tissue sources ranging from zygotes to spe-
cific tissues (bone marrow, adipose, amniotic fluid, skin, liver, bone, cartilage etc.). Embryonic stem cells are derived from embryos at early stage where
less than 100 cells are present, followed by foetal stem cells that are taken from the genital ridge section from 5 to 8 weeks of gestation (drawing mod-
ified from http://commons.wikimedia.org/wiki/Image:10_weeks_pregnant.jpg donated by wouter.vengeer@tribal.nl with a free license). Tissue-specific
foetal cells are taken following 9 weeks of gestation usually up to 14–16 weeks from normal tissue. Adult stem cells can be isolated from most tissue
sources but are rare with only 1 in every 104 to 105 of total cell volume.
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Other adult stem cells, frequently referred to as MSC, have raised
hopes for new treatments because they a have high self-renewal
capacity and can generate multiple cell lineages. They can be isolated
not only from bone marrow but also from many tissues such as
amniotic fluid, adipose tissue, brain, skin, heart, kidneys and liver.
Although widely distributed, adult stem cells represent only a small
fraction of a tissue cell population (many times only 1 in every 104 to
105 cells), thus requiring extensive in vitro separation and expansion
steps [152]. Stem cell cultures are technically demanding.
Maintenance and expansion of stem cells in an undifferentiated state
requires the addition of many specific GFs [153]. Culture of these
cells without feeder layers (which are usually formed by animal
cells), is difficult and feeder layers are responsible for some aspects
of inconsistent colony cell growth. The necessity of using exogenous
GFs as well as animal products is a limiting factor for the scale up of
stem cell cultures for clinical applications [138].
Unlike stem cells, foetal cells are differentiated cells with high
expansion and regeneration and low immunogenic properties
[154]. They can be isolated from foetal tissues, which follow
embryonic stage after 9 weeks of development. Foetal cells 
have extensive expansion capabilities and cell culture require-
ments are minimal compared to stem or mesenchymal cell types.
As the foetal cells are already differentiated and do not need to be
directed or altered, the vast number of additional GFs normally
necessary are not needed for cell culture and expansion [146]. Cell
choice is of utmost importance and each element of processing
necessitates special attention in order to produce a safe, consis-
tent and successful cell therapy for clinical trials [155].
Specific features of bone cells needed to be
advantageous for clinical use
As whole bone marrow transplantation may not be optimal 
biologically, the expansion of bone marrow osteoprogenitors has
been evaluated. The procedure is laborious as their isolation and
characterization has been difficult due to their low numbers in the
original tissue and lack of specific reactive antibodies to assure
separation of active cellular components. Patient treatment is only
possible following 4–6 weeks of expansion in cell culture.
Demonstration of cell function is of particular importance so that
separated cells are shown to be capable of matrix deposition, 
mineralization, ossification, nodule formation and bone formation
in vivo without fibrous tissue formation. Although these cells have
been shown to fulfil the required needs, it is labour intensive to
use these procedures for each individual patient.
More recently, femurs from foetal tissue of ~8 weeks were evalu-
ated for isolation of bone progenitors and thus these cell populations
would be formally considered as foetal stem cells (5–8 weeks)
[156]. Mirmalek-Sani et al. have shown that these cells histologi-
cally resemble cartilage and this was confirmed by the high plastic-
ity seen with these cells when compared to studies using foetal
bone cell populations derived from 12- to 14 week gestation
femurs. In vivo mineralization of 8 week stem cells is seen with
osteoinductive media but with 12–14 week foetal bone cells such
media are not necessary because spontaneous minerialization is
seen without external GFs [157]. Spontaneous behaviour of cells is
thus important to eliminate the use of multiple GFs and increase
biosafety while reducing the cost of cell production. It is advanta-
geous to use differentiated cells with lower plasticity as they
depend less than undifferentiated cells on the many environmental
factors such as nutrition, mechanical loading, inflammation, angio-
genesis and interaction with endogenous cells. In addition, foetal
bone cells from 12 to 14 weeks have been extensively evaluated 
in vivo for immunological privilege, safety and osteoinduction.
Montjovent et al. [158] have demonstrated that a composite
made of poly-L-lactic acid and -TCP particles used as scaffolds
to seed foetal bone cells can offer suitable conditions for
osteoblasts to achieve full differentiation due to the high
osteogenic potential of these cells. Furthermore, in vivo studies
using dedicated foetal bone cell banks and a solid matrix have
shown significant promotion of bone growth using two different
model systems [158]. Safety studies in a large animal model using
sheep have also shown that 12 week foetal bone cells derived from
a dedicated cell bank are immunologically accepted, do not form
fibrous tissue and promote biological activity with bone growth
(personal communication by Applegate and Pioletti).
Development of therapeutic biological agents
Organ donation, whole cell bioprocessing and procedures adapt-
able to good manufacturing processes (GMP) make it possible to
develop extensive master cell banks and working cell banks to
facilitate thorough testing (Fig. 5) [159]. Once master cell banks
can be produced, working cell banks can be produced to establish
individual batches for treatment of large numbers patients (thou-
sands from one cell bank). Further, these cell banks can be tested
completely for safety regarding sterility, pathogens and adventi-
tious agents and tumorigenicity. Once safety can be assured, effi-
cient cell presentation with biocompatible delivery systems can be
assessed for specific tissues. For delivery systems, biocompatible
biomaterials need to be available in order to provide an extracellu-
lar matrix environment for cell differentiation, delivery and release.
Cells and materials need to be tested together to not only assure
biocompatibility but also their interactions, cellular stability,
possible degraded by-products of combination and degradation or
absorption. Ease of applicability of the final product will be of
importance for clinical use.
All cellular products must be in compliance with GMP guidelines
with respect to medicinal products and investigational medicinal
products for human use. The European Union (EU) regulation on
advanced therapy medicinal products was adopted by all European
Member States on December 30, 2008 and the United States Food
and Drug Administration (FDA) recently also proposed regulations
on human cells, tissues and cellular and tissue-based products
[160–164]. The main scope of these regulations is to establish clear
classification criteria for many new cell-based medicinal products.
For the EU, it makes reference to the 2004/23/EC directive on dona-
tion, procurement and testing of human cells and tissues and also
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with directive 2002/98/EC on human blood and blood components.
These directives dictate that human cells used for therapeutic pur-
poses must be in compliance with the quality requirements they
describe and that all advanced therapy medicinal products must be
prepared under GMP conditions [161, 165, 166]. Key elements for
cellular-based products include identity, purity, sterility, stability,
safety and efficacy are recommended. In all, these new regulations
impose strict criteria for the production and the environment used
for the production of cell-based products to be used in clinical tri-
als and treatments [167, 168].
Clinical application concerns
Risk assessment of final cellular products for human use is of
utmost concern. Self-renewal of undifferentiated cells represents
potential for tumour formation. Certain techniques such as cellu-
lar cloning or encapsulation of cellular products are alternatives to
assure safety. Many cell-based therapies will not consist of a uni-
form cell population. Associated accessory cells raise additional
questions for potential risk as well as their physiological role after
administration. Cellular death of transplanted cell populations,
ectopic tissue formation or migration from the site of administra-
tion could be a problem when cellular therapies are used within
anatomically sensitive areas such as the central nervous system,
joints or myocardium. Pre-clinical animal models for specific
pathologies or tissue repair are an important step and special care
must be taken in the interpretation of pertinent safety and biolog-
ical activity. A thorough appreciation of relevant advantages and
limitations must be made regarding an animal model choice.
Conclusions
Cell-based therapies are being developed and introduced for all
types of tissue repair including skin, bone, cartilage, muscle and
Fig. 5 Organization of a cell therapy platform. Director of technical and logistics coordinates the program with essential legal and ethical advisors and a
medical director for interpretation of medical quality assurance (serology and pathology reports). The separation of hospitals for the organ donation and
all other aspects of the platform including serology, pathology and the GLP cell culture laboratory can assure complete anonymous and coded organ dona-
tions. Importantly, the Director of Technical and Logistics is not involved in any manner in the organ donation process as required by law. Final approval
for use of validated cell banks for human therapy is coordinated and approved with both Hospital Ethics Committees and National regulatory agencies
(i.e. European Medicines Association, Food and Drug Administration, SwissMedic [32]).
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spine. They offer promise for repairing and/or replacing damaged
tissue and restoring lost functionality. One of the major challenges
for assuring that more patients will benefit from cell-based thera-
pies in the future will be the optimization of the choice of cell type
as well as methods for their isolation and expansion. Today, it is
still unknown what type of osteogenic cell will be the most suitable
for engineering bone tissue. MSC, foetal-stem and foetal cells,
bone marrow stromal cells, periosteal cells and osteoblasts have
been successfully used for generation of bone tissue. Isolation
and expansion efficiency, stability of osteoblastic phenotype, in vivo
bone formation capacity and long-term safety are essential
requirements that have to be met by any type of osteogenic cell for
successful clinical application.
Equally important is the delivery system for the cell of choice
and their interaction with scaffolds to assure biocompatibility. The
development of master cell banks from the cells of choice provides
a major advantage for the creation of a therapeutic biological
agent. Careful selection of donors and extensive screening of both
the donor and cultured cells avoids transmissible viral, fungal or
bacterial disease and therefore can provide a safe and secure 
utilization of cells for therapeutic purposes. Clear regulatory over-
sight of cellular use, particularly for organ donation, embryonic
and foetal cells will be necessary. Overall, cooperative interdisci-
plinary efforts and cooperation to form successful translational
medicine platforms in universities and hospitals will serve to
ensure further patient safety.
Platelet-rich plasma (PRP), growth
factors and osteogenesis
PRP is a concentrate of platelets in a small volume of plasma from
freshly drawn whole blood activated with a mixture of thrombin
and calcium [169]. PRP is used to facilitate wound and bone 
healing, thanks to the molecules released by platelets during acti-
vation. A number of these substances affect osteogenesis, such as
TGF-1, PDGF-BB, VEGF-A and IGF-I (Table 1). These molecules
are more concentrated in PRP than in a normal clot as a result of
the higher platelet number. After release, they are trapped within
the fibrin mesh, then slowly pass into the microenvironment and
bind to receptors on the cell membrane. The molecules released
by platelets regulate key processes involved in tissue repair,
including chemotaxis, cell proliferation, differentiation and extra-
cellular matrix synthesis (Table 1). The fibrin mesh itself can act
as a conductive matrix or ‘scaffold’ for cell adhesion [170].
The combination of GFs in PRP is in an optimal level and ratio,
and seems to be more efficient than the single rhGF, owing to their
synergistic effects [87]. The technique for obtaining GF from PRP
is relatively simple and less expensive than rhGF. Because of its
autologous origin, PRP does not hold any risk of immunological
reactions and transmissible diseases. The drawbacks of PRP are
the high variability of GF concentrations, due both to individual
factors and to different preparation methods [171]. We found a
high variability in PDGF-BB and TGF-1 levels assayed in the
supernatant of thrombin-activated PRP, on lysates of platelet con-
centrates, on serum and platelet poor plasma from 11 healthy
individuals and from 11 patients with osteonecrosis (Table 2).
The original Marx protocol obtained PRP by the addition of 
calcium and thrombin to a platelet concentrate [169]. Recently,
other protocols for PRP preparation have been proposed, which
differ for anticoagulant [172], leucocyte depletion and platelet 
activators [173, 174]. Leucocyte depletion avoids the release of
pro-inflammatory cytokines [175]. However, some authors suggest
that leucocytes represent an additional source of GF and have an
important role in host immune defence [176]. Myeloperoxidase
contained in neutrophils and monocytes generates reactive oxygen
species, that act as potent bactericidal and may be helpful to pre-
vent post-surgical infections and in the prophylaxis and treatment
of infection-related delayed healing and non-union [177].
PRP effects in vitro on the cells involved 
in bone repair
PRP effects on osteoblasts
The use of PRP was proposed in order to provide a microenviron-
ment for the orchestration of the sequential process of bone
regeneration involving migration, proliferation and differentiation
of osteogenic cells. The mitogenic effect of PRP was demon-
strated by in vitro studies on hMSC [178, 179] and human trabec-
ular osteoblasts [180]. Among the GF released by platelets, the
highest contribution to the proliferation of osteoblasts was from
PDGF and TGF-1 [181].
Table 1 The role in bone remodelling of the GFs and other molecules
released by platelets
Molecule Role in bone remodelling
TGF-
Mesenchymal stromal cell proliferation; osteoblast
precursor recruitment; osteoblast and chondrocyte
differentiation (but inhibition of terminal differenti-
ation); bone matrix production; recruitment of
osteoclast precursors but inhibition of terminal
differentiation and induction of apoptosis
PDGF
Osteoprogenitor migration, proliferation and 
differentiation; osteoclastogenesis
VEGF
Conversion of cartilage into bone; osteoblast 
proliferation and differentiation
IGF
Osteoblast proliferation; bone matrix synthesis;
bone resorption
EGF Osteoblast recruitment and proliferation
Fibronectin Osteoblast migration and adhesion
Vitronectin Osteoblast migration and adhesion
Prostaglandin E2 Bone resorption
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In vivo platelet effects are likely restricted to the early stages
of bone regeneration until the blood clot is replaced by granula-
tion tissue, which is rich in osteogenic progenitor cells and
blood vessels. Similarly, in vitro PRP increased MSC prolifera-
tion but inhibited differentiation [182]. PRP seems to have 
opposite effects than BMPs. PRP stimulated migration and pro-
liferation of the osteogenic cell line MC3T3-E1, whereas BMP did
not have any effect on migration and induced only a moderate
increase of proliferation. However, PRP suppressed ALP activity
in response to BMP. Together, these findings indicate that 
activated platelets can influence the microenvironment in such a
way that osteogenic differentiation is suppressed. Once platelet
GF have lost their activity, osteogenic cells can regain their
responsiveness to BMP [183].
A PRP enriched in fibrin better stimulated proliferation and
mineralization of rat osteoblasts than soluble PRP, probably due to
a more gradual release of GF from the fibrin component [184].
Additional signals derived from the microenvironment modulate
the effects of PRP. hMSC proliferation was increased by the com-
bination of platelet concentrates and demineralized bone matrix,
but osteoblastic differentiation decreased [185]. On the contrary,
the authors observed that the combination of PRP and freeze-
dried bone allografts accelerated MSC differentiation, as demon-
strated by the significantly higher osterix expression at 15 days,
and sustained autonomous production of GF by the cells them-
selves, as shown by the higher level of FGF-2 in the conditioned
culture medium after 11 days [186].
In bone engineering, PRP represents a source of GF to be
added to MSC seeded on an artificial scaffold, which could
modulate the effects of PRP owing to its physical and chemical
properties. PRP favoured the adhesion and proliferation of 
MSC on three-dimensional ceramic scaffolds with high specific
surface area, such as calcium-deficient HA, in comparison with
scaffolds with lower specific surface area, such as -TCP [187].
The effect of PRP lysates on the osteogenic differentiation of
goat MSC on HA and silica-coated HA was lower than that of 
fibrin glue, which represents an extracellular matrix with 
arginine–glycine–aspartic acid motifs that can bind to integrins
favouring cell adhesion [188]. However, in clinical use platelet
gel preparation generally involves fibrin clotting; therefore
platelet gel has the advantages of both platelet concentrates 
and fibrin mesh.
PRP effects on osteoclasts 
Activated platelets affect osteoclasts through the release of modula-
tors of osteoclast differentiation, such as TGF-1, IGF-I, PDGF [189]
and prostaglandin E2. VEGF favoured osteoclast differentiation in
the presence of macrophage colony-stimulating factor [190].
Conflicting results have been reported about the effect of PRP
on osteoclasts. In vitro, PRP was shown to favour osteoclast 
differentiation of mouse bone marrow cells, particularly the 
generation of tartrate-resistant acid phosphatase (TRACP) mult-
inucleated cells, the formation of bone pits and the expression of
mRNA for cathepsin K and matrix metalloproteinase-9 [191, 192].
However, other authors found that PRP decreased the generation
of TRACP multinucleated cells from rat bone marrow and
enhanced the secretion of osteoprotegerin from osteoblasts [193].
From research on the osteoclast precursors of human peripheral
blood, 10% PRP interfered with the complete differentiation
process and osteoclast activation, as shown by the decrease of
bone collagen type I degradation. At higher dosage PRP affected
osteoclast formation also at an early stage of differentiation so that
it particularly impaired the fusion of precursors and the formation
of TRACP multinucleated cells [194]. These results suggest a
possible inhibitory effect of the substances released by PRP on
osteoclast activation.
In vivo, dogs with mandibular defects treated with autologous
bone grafts and PRP initially showed an increase of osteoclast
number, but after 2 months there was no significant difference
between PRP- and non-PRP-added grafts [195].
On the basis of these results, we suggest that PRP can have
opposing effects on osteoclast generation and differentiation
through the simultaneous interaction of several released mole-
cules with osteoclast precursors. TGF-1 could be a possible
inhibitor of terminal differentiation of osteoclasts, because TGF-1
has been shown to favour the recruitment of haematopoietic pre-
cursors [196] but to inhibit bone resorption [197].
PRP effects on endothelial cells
Angiogenesis is crucial for good bone healing. Newly formed ves-
sels mediate delivery of cell precursors, secrete GF and transport
nutrients and oxygen [198]. Endothelial cells synthesize molecules
which affect bone cells, such as cytokines, chemokines,
prostanoids, GF, adhesion molecules, matrix constituents [199],
endothelin-1 [200] and BMP-2 [201].
Table 2 Mean and standard deviation of TGF-1 and PDGF-BB in healthy individuals and in patients with osteonecrosis
Sample
TGF-1 ng/ml PDGF-BB ng/ml
Healthy individuals Osteonecrosis Healthy individuals Osteonecrosis
Thrombin-activated PRP supernatant 31.4 
 38 78.8 
 70.8 6.7 
 3.2 9.6 
 4.4
Lysate 99.1 
 68.2 120.5 
 83 10.8 
 6.3 12.4 
 3.9
Serum 25.9 
 15.1 37.6 
 18 2.3 
 0.5 4.8 
 3.2
PPP 2.6 
 1.2 2.4 
 1.5 0.7 
 0.3 0.9 
 0.7
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The GF released by platelets, such as VEGF, TGF-, PDGF and
EGF [202], not only have pro-angiogenic properties [203–205],
but also induce the endothelial cells to express a pro-osteogenic
phenotype. PRP induced human umbilical endothelial cells
(HUVEC) to express PDGF-, which in turn has chemotactic
effects [206], recruiting MSC to the site of bone repair. MSC
migration was higher in HUVEC incubated with PRP in compari-
son with HUVEC incubated with low serum medium or with PRP
[207]. PRP favours monocyte adhesion to the vessel wall, through
the stimulation of endothelial cell expression of intercellular 
adhesion molecule 1 [207], which is important because the 
monocyte/macrophage response is essential for bone repair.
PRP effects in vivo on experimental animals
The results of research on osteogenic activity of PRP in animals
are conflicting. In combination with bovine cancellous bone, PRP
increased bone formation in a non-critical-size bone defect in rab-
bit cranium [208]. However, other authors noticed that the use of
bone graft material in combination with PRP was not superior to
that of bone allograft alone [209–211]. These different results may
depend on the animal species used, the method of gel preparation,
type of bone defect, outcome parameters measured, the presence
of MSC and of scaffolds or bone substitutes. An important reason
for the discordant results from different authors is the fact that
critical-size bone defects were not assayed. When critical-size
bone defects were tested, the combination of PRP, bone substitutes
and MSC induced the greatest improvement in healing compared
to a single component assayed alone [212]. Another variable
seems to be the ratio of bone graft to PRP [213].
When PRP was used in combination with artificial scaffolds,
the physical and chemical properties of the scaffold material
should be considered because they can affect the performance of
PRP [187]. When PRP was used in association with -TCP [214]
or triphasic ceramic- (calcium silicate, HA and TCP) coated HA
[215], more intense bone regeneration was observed.
Even though it is generally assumed that PRP might support
osteogenesis in the presence of precursor cells, sometimes the
addition of PRP to MSC did not further increase the rate of
bone formation in comparison to MSC alone. In goats no effect
was shown when PRP was added to MSC seeded on scaffolds
made of the combination of HA and -TCP implanted at an
orthotopic or ectopic location [216]. MSC added to the critical
size defect were likely already induced towards osteogenesis
and PRP could not significantly increase this. Moreover,
osteotomy might recruit osteoblast precursors from the bone
marrow [217].
The effect of PRP combined with BMSC was also tested in
experimental dental implant models. In a dog mandible model of
bone defects, the combination of canine MSC and PRP favoured
well-formed mature bone formation and neo-vascularization,
comparable with that induced by autologous cancellous bone,
whereas PRP alone performed poorly [218]. In other experiments,
the combination of MSC-PRP-fibrin gel, used as grafting material
for alveolar augmentation in adult dogs, lead to the highest degree
of direct bone-implant contact [219].
From the analysis of the results of in vivo research, it can be
concluded that PRP promotes bone healing [220], particularly in
the early phase [221] and in combination with MSC and bone
grafts [222, 223] or an artificial scaffold. In the later course of
bone healing, the PRP effects were less evident [224, 225].
However, a beneficial effect of PRP on bone healing was not
demonstrated in every animal model and with every bone substi-
tute, probably owing to the differences in the protocol design and
the method for measuring bone formation [226].
The clinical use of PRP for bone repair
In orthopaedics, PRP is generally considered a tool for promoting
bone repair, even though there have been discordant or inconsis-
tent results [227]. PRP, sometimes combined with MSC, has been
proposed for the treatment of non-unions [228], in femoral and
tibial lengthenings [229], in distraction osteogenesis, in spinal
fusions, in foot and ankle surgery and in joint arthroplasties. PRP
is also used in odontostomatology and maxillo-facial surgery, to
improve bone regeneration.
Non-union
The scientific basis for the use of PRP in non-unions and
pseudoarthrosis is the significant reduction of GF which has been
observed at the non-union sites, in comparison with the site of
fresh fractures [230]. In non-unions, both PRP administration
during surgery together with bone allograft and percutaneous
administration of PRP have been proposed. PRP with autologous
bone graft gave resolution of non-unions of the foot and ankle 
at a mean of 60 days [230]. With percutaneous administration
healing was improved only if the treatment was performed within
11 months after the initial surgery [231]. In a prospective study,
PRP, injected into atrophic non-unions, treated with percutaneous
stabilization, failed to improve consolidation [232]. Therefore, at
present there is no clinical evidence of benefit of PRP in non-
unions in comparison with other treatments. An important issue is
the option to treat with PRP or recombinant BMP. The preliminary
results of a recent prospective randomized clinical study on 
120 patients, where PRP was compared with rhBMP-7 for the
treatment of persistent long bone non-unions, supported the view
that the application of rhBMP-7 was superior to PRP [233].
Distraction osteogenesis
In distraction osteogenesis of the femur or tibia, for patients with
achondroplasia, hypochondroplasia or congenital pseudoarthrosis,
PRP in combination with MSC resulted in acceleration of new
bone regeneration [234].
Spinal fusion
In a prospective study on lumbar interbody fusion, PRP with an
allogeneic bone graft gave a clinical and radiological outcome at
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12 and 24 months comparable to an autologous graft [235].
However, other researchers failed to show an enhancement in lumbar
fusion using autologous bone graft with or without PRP [236].
Foot and ankle surgery
In total ankle arthroplasty PRP improved the syndesmosis union
rate [237, 238]. PRP may help to achieve an acceptable time for
fusion also in high-risk patients with diabetes, immunosuppres-
sion, malnutrition, alcohol abuse, osteomyelitis and history of
impaired osseous healing or multiple same site surgeries [239].
Total knee arthroplasty
The primary indication for use of PRP in total knee arthroplasty is
to promote wound healing and to decrease blood loss. A study of
71 patients treated with PRP fibrin sealant, which was sprayed in the
knee just prior to closure, showed not only higher post-operative
haemoglobin levels, but also a significantly greater knee range of
motion compared with the untreated group after 6 weeks [240].
Odontostomatology and maxillofacial surgery
PRP has been largely applied to promote bone regeneration in
odontostomatology and maxillofacial surgery. MSC and PRP
applied simultaneously with titanium implants provided stable and
predictable results in terms of implant success [241]. Implants of
-TCP seeded with MSC and PRP for maxillary sinus floor aug-
mentation were clinically stable 12 months after loading [242].
Recently, PRP associated with cancellous marrow grafting has
been proposed in selected cases of osteonecrosis of the jaws
[243]. A systematic review of human controlled clinical trials
designed to treat maxillofacial bony defects with the application of
PRP found evidence for beneficial effects in the treatment of peri-
odontal defects, but minimal effects in sinus elevation [244].
There are few randomized, controlled studies of the clinical
effects of PRP, and the apparent discrepancies reported in clinical
effects and the diverse success rates among the different
orthopaedic and maxillofacial applications could be a function of
the different PRP preparation methods, poor characterization of
the platelet concentrate used, the presence or absence of fibrin
glue, the presence or absence of leucocytes, the presence or
absence of MSC, the presence or absence of bone allografts or
scaffolds (and what scaffold) and differences in the primary 
outcome measured. In addition, the power of different studies
varies considerably. Although there are a number of studies in
orthopaedic patients, the majority of them are anecdotal and only
a few are well-designed controlled clinical trials. A recent system-
atic literature review on the use of PRP in orthopaedic surgery,
after the exclusion of the applications in periodontal and maxillo-
facial surgery, identified 39 articles concerning clinical trials [245].
Only one was a randomized controlled study [246], which demon-
strated that PRP, particularly if combined with MSC, increased the
osteogenic potential of lyophilized bone chips. The strength of this
clinical research was the randomization and the comparison
among different treatments (freeze-dried bone allograft alone or in
combination with PRP with or without MSC); its weakness was the
lack of the evaluation of PRP effect in alone and of a clear primary
outcome. More well-designed, prospective, rigorous clinical trials
using consistent techniques may lead to more conclusive general
recommendations [247].
Conclusion
PRP has been evaluated through in vitro, in vivo and clinical models
of bone regeneration, with conflicting results. PRP use appears to
be safe and feasible and may have a beneficial therapeutic effect,
particularly in the early phases of bone formation. In vitro data have
demonstrated that PRP, in addition to the stimulation of cell
growth, induces target cells to synthesize GF and other substances
able to sustain bone healing. The best in vivo and clinical results
are obtained when PRP is added to MSC and osteogenic scaffolds
or bone allografts. Further basic science and clinical research is
needed to define the clinical indications, the methods of prepara-
tion and administration and the primary outcome with PRP.
Molecular control of osteogenesis
The timeline of molecular events that regulate osteogenesis has
been described by Li et al., who analysed the ‘fracture healing
transcriptoma’ and the ‘fracture healing proteoma’ by comparing
non-fractured and post-fractured rat femurs during early and late
stages of bone repair [248, 249]. In early phases after the bone
injury, they observed an up-regulation of genes related to cell-
cycle and cell-to-cell signalling, supporting the assumption that
both cell division and cell communication are essential to initiate
fracture healing. Many of the genes controlling cell growth and
survival are constantly up-regulated, whereas those functionally
associated with differentiation of osteogenic precursors and bone
matrix formation undergo temporary modulation over time. In 
particular, expression of IGF-I and IGF-II, PDGF, FGFR, fibronectin,
matrix metalloproteinases, glypican, byglican, osteomodulin,
osteonectin, tenascin C, cartilage collagen (types VI and XI) and
bone collagen (types I, V, VI and XII) increase until the immature
osteoid synthesized by osteoblast progenitors is histologically
detectable. The start of endochondral ossification is marked by a
number of molecular pathways, but p38/MAPK (mitogen-activated
protein kinase) signalling plays a pivotal role in advancing the
process to this phase. Even though recent studies clearly demon-
strated that native MSC are phenotypically and functionally different
from cultured MSC [250], the time course and extent of gene
expression in in vitro expanded osteogenic precursors is not 
significantly different from that which has been observed in vivo
[251]. The gene expression profile of hMSC undergoing
osteogenic induction has been analysed at different time-points
until MSC were able to form mineral nodules [252]. As expected,
in the early stage of differentiation most of the up-regulated genes
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are related to cell proliferation, whereas in later stages the expres-
sion of genes with a biological function relevant to osteogenesis,
such as GF-signalling pathways, bone related genes and adhesion
molecules, gradually increases (Fig. 6). In recent years the most
important pathways which are known to play important roles in
driving the osteogenic differentiation of MSC have been identified
by in vitro and in vivo studies [253–258].
TGF- signalling
The TGF- superfamily is a large family of growth and differentiation
factors including 34 members at least [259]. BMPs are members
of the TGF- superfamily and have a strong impact on osteoprog-
enitor differentiation, although it has been shown that osteogene-
sis is initiated normally in BMP-deficient mice [250]. In addition,
BMPs are able to modulate bone formation, e.g. BMP-2, BMP-7,
BMP-6 and BMP-9 show positive effects on the osteogenesis, in
contrast to the inhibitory activity of BMP-3. The BMP/TGF-
superfamily signalling is transduced through two types of
serine/threonine kinase receptors: type I receptors are BMPR-IA
or ALK-3, BMPR-IB or ALK-6 and type IA activin receptor (ActR-IA
or ALK-2); type II receptors are BMPR-II, ActR-II and ActR-IIB.
Whereas BMPR-IA, BMPR-IB and BMPR-II are specific to BMPs,
ActR-IA, II and IIB are also signalling receptors for activins. Type II
receptors bind ligands in the absence of type I receptors, but they
require their respective type I receptors for signalling, whereas
type I receptors require their respective type II receptors for ligand
binding [260]. The ligand-receptor complex acts through Smad
proteins which are transcriptional modulators. There are three
classes of Smads: (i) receptor-regulated Smads (R-Smad), that
can be activated by BMP (BMPR-Smad 1, 5 and 8), or TGF-
(TGFR-Smad 2 and 3); (ii) common partner BMP and TGF-
mediator Smads (Co-Smads), such as Smad 4; (iii) inhibitory
Smads, such as Smad 6 and 7 [261]. Phosphorylated R-Smads
bind to the common partner Smad 4, and the complex translo-
cates into the nucleus and regulates transcription of target genes
by interacting with various transcription factors (see afterwards).
Although the Smads are critical mediators in the TGF- signalling
pathway, BMP-2 can activate Smad-independent pathways,
including MAPK that have distinct roles in regulating ALP and OC
expression in osteoblastic cells [262].
Fig. 6 Schematic representation of the principal signalling networks and transcription factors regulating osteoblast differentiation and osteogenesis (see
text for details). Lines with arrowheads indicate a positive action, lines with bars indicate an inhibition and dashed lines indicate that function has to be
proven. The lineage commitment and the differentiation of cultured MSC are signed by the acquisition of specific osteoblast functions. In boxes are shown
genes that are significantly up-regulated during osteogenic differentiation of MSC. The ‘Gene Ontology Annotation’ of genes listed here is associated to
GF-signalling pathways, cell communication and skeletal development. The up-regulated genes have been grouped according to the differentiation status
of cultured MSC: ‘Pre-osteoblasts’ are MSC which are able to produce ALP (cytochemical activity, 10) and generate ‘Colony Forming Units’;
‘Differentiated osteoblasts’ are cells which have the competence to deposit mineral nodules in vitro (von Kossa staining, 10). Genes are reported with
the official symbol, as shown in ‘Gene’ database (http://www.ncbi.nlm.nih.gov/sites/entrez?dbgene).
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FGF signalling
The FGF gene family is composed of 23 members that variously
bind to seven FGF tyrosine kinase receptor isoforms (Fgfr) [263].
The FGF-family polypeptides play a critical role in regulating endo-
chondral and intramembranous ossification. Fgfr1 is expressed in
hypertrophic chondrocytes, and Fgfr1 signalling has stage-
specific effects on osteoblast maturation, because it acts either to
stimulate differentiation in osteoprogenitor cell or to arrest the
maturation of differentiated osteoblasts [264]. FGFs 2, 9 and 18
probably bind Fgfr1 in osteoblasts. FGF9 and FGF18 are expressed
in the perichondrium/periosteum, and seem to play a predominant
role during the embryonic skeletogenesis [255]. FGF2 is
expressed in periosteal cells and osteoblasts, and its activity
should be more relevant during postnatal stages, as proven by the
decreased ability to mineralize in vitro which has been observed in
MSC cultures from FGF2-null mice [265]. Fgfr2 is expressed in
reserve chondrocytes and appears to be down-regulated in prolif-
erating chondrocytes. Fgf2r shows tissue-specific alternative
splicing and the mesenchymal variants are the Fgfr2c forms,
which are activated by FGF2, 4, 6, 8 and 9. FGF18 acts as a phys-
iological ligand for Fgfr3, which regulates cell growth and differ-
entiation of proliferating chondrocytes, whereas in differentiated
osteoblasts it regulates bone density and cortical thickness [266].
IGF signalling
The IGF family consists of two secreted GFs, namely IGF-I and
IGF-II, two receptors (IGF1R and IGF2R) and six high-affinity bind-
ing proteins. Both IGFs are expressed by osteoblasts and show
similar biological activities, even though IGF-I is more potent than
IGF-II. They stimulate osteoblast function and bone matrix depo-
sition favouring the synthesis of collagens and non-collagenous
proteins [267]. IGF-I does not influence the differentiation of MSC
into osteoblasts and cell proliferation, which instead is stimulated
by IGF-II [5]. Actions of both IGFs are mediated by the IGF-I recep-
tor, a ligand-activated tyrosine protein kinase that uses a series of
intracellular adaptor molecules, including the insulin receptor sub-
strate proteins IRS1 and IRS2, to engage downstream signalling
pathways [268]. IGF-I utilizes both the P13K, which induces the
activation of Akt, and the MAPK pathway, which activates p38,
Jun-N-terminal kinases and ERK1/2. The use of each pathway is
dependent on culture conditions and the stage of cell differentia-
tion [267]. Studies in experimental animals have concluded 
that action of IGF is essential for normal bone formation, growth
and maintenance.
PDGF signalling
PDGF is an extracellular factor which exists as three biologically
active isoforms composed of PDGF-A and PDGF-B polypeptide
chain. Binding of PDGF requires and results in the dimerization of
the two distinct receptors (-PDGFR and -PDGFR) that form
three distinct receptor patterns (, , ). MSCs express 
and  receptors. Although PDGF signalling has been reported to
play an important role in the control of various cell functions of
skeletal cells, the network of PDGF signalling for MSCs has not
been fully clarified. PDGF-BB, but not PDGF-AA, inhibited
osteogenic differentiation accompanied by decreased ALP activity
and mRNA levels The depletion of PDGFR- gene in MSC
decrease the mitogenic and migratory responses and enhanced
osteogenic differentiation, as evaluated by increased ALP activity
and mRNA levels, OC, BMP-2, Runx2 and Osx [269]. More recent
data show that the pharmacological inhibition of PDGFR
decreases the MSC proliferation induced by PDGF-BB, but does
not affect the osteoblastic differentiation, as evaluated by
analysing the expression of other osteogenic marker genes and
the mineralized matrix production [270].
MAPK signalling pathway
MAPK pathway is activated by a variety of GFs with a role in
osteogenesis, including FGF, PDGF, TGF- and IGFs. The 
extracellular stimuli lead to the activation of a signalling cascade
composed of MAP kinase, MAP kinase kinase (MKK or MAP2K)
and MAP kinase kinase kinase (MKKK or MAP3K) [271]. The
physiological functions of this complex cascade are summarized
in Table 3.
Wnt signalling pathway
Wnts (for wingless) forms a large family of secreted molecules,
which are ligands for the membrane-spanning frizzled (FZD)
receptors involved in various aspects of cellular biology, includ-
ing cell growth, differentiation, function and death. Wnts can
transduce their signals through two different pathways, namely
‘canonical’ and ‘non-canonical’ Wnt signalling. The first one
involves the formation of a complex among Wnt proteins, FZD
and low density Lrp5 or Lrp6 receptors. There is considerable
evidence indicating that Wnt canonical pathway plays a critical
role in bone formation resulting in the expression of osteoblast-
specific markers [272, 273]. The binding of Wnt proteins to 
the FZD/Lrp5/6 complex generates a signal, which inhibits the
activity of glycogen synthase kinase 3 (GSK-3). GSK-3 inactivity
blocks the phosphorylation of -catenin, and prevents its degra-
dation in the cytoplasm by the ubiquitin-pathway, leading to
translocation of -catenin into the nucleus where it cooperates
with transcription factors of the T-cell factor/lymphoid enhancer
factor family [274]. The -catenin activity seems to be a require-
ment to direct the bipotential osteochondroprogenitor towards a
specific lineage. Indeed, the -catenin/T-cell factor 1 complex
enhances expression and activity of the osteogenic promoter
Runx2, whereas low levels of -catenin direct the mesenchymal
precursors toward chondrogenesis [275].
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Hedgehog signalling
Hedgehog signalling (Hh) family members provide positional
information during the skeletogenesis, and initiate or maintain cel-
lular differentiation programs regulating the formation of cartilage
and bone. Indian hedgehog (Ihh) is produced by pre-hypertrophic
chondrocytes and its signalling appears to act directly on
osteoblast progenitors located in the perichondrium [276, 277].
The pathway is triggered by binding Hh protein to its receptor
Patched thus activating the seven-transmembrane protein
smoothened (Smo). The Hh signal transduction cascade activates
the transcription factor GliA, a member of the Kruppel family of
zinc finger proteins, which is translocated into the nucleus, regu-
lates stem cell proliferation and activates gene targets. Several
pieces of data show that Ihh signalling and Wnt signalling cooper-
ate in controlling various aspects of skeletal development.
Interestingly, Smo receptors have considerable amino acid
sequence similarity with the Wnt receptor FZD, and GSK-3 is
able to inhibit the Hh signalling [250]. Experimental data prove
that Ihh signalling acts upstream of Wnt signalling and its activity
seems to be limited to the early stage of osteoblast commitment
[278]. In fact, when Smo activity is removed in Osx osteoprog-
enitors, normal osteoblasts are generated and the endochondral
skeleton at birth is indistinguishable from wild-type [279].
Notch signalling
Notch signalling is well known for determining cell fate. Because
Notch receptors and their ligands (	1, 3, 4 and Jagged 1, 2) are
transmembrane proteins, a cell–cell interaction is required for
activating signalling cascade [280]. Notch 1 and Notch 2 are gen-
erally expressed in osteoblasts, whereas Notch 3 and Notch 4
have been found in subsets of the osteogenic lineage [281].
Experimental data support a dimorphic function of Notch sig-
nalling, which is able to up-regulate bone related genes, to favour
the proliferation of immature osteoblasts, and to induce a severe
osteosclerosis, but also to repress the BMP-induced osteoblast
maturation by inhibiting the Runx2 transactivation function [282].
Ephrin signalling
There are two classes of ephrins: the B class (B1 to B3) are ligands
for EphB1–6 tyrosine kinase receptors, whereas the A class (A1 to
A5) are ligands for GPI-anchored EphA receptors (A1 to A10).
Ephrins have the capacity of bidirectional signalling. Thus, when a
cell expressing an Eph receptor contacts a cell expressing an
ephrin ligand, signals are transduced into both cells by forward and
reverse signalling, respectively [283]. The reverse signalling from
EphB4 in osteoblasts to ephrinB2 in osteoclast progenitors leads to
the inhibition of osteoclast differentiation, whereas the forward sig-
nalling through EphB4 induces osteogenic transcription factors
[284]. However, ephrinA2–EphA2 interaction facilitates the initia-
tion phase of bone remodelling by enhancing osteoclast differenti-
ation and suppressing osteoblast differentiation [285].
Transcription factors regulating osteoblast 
differentiation
The signalling pathways described above lead to the activation of
transcription factors that exert positive and negative regulatory
effects on the expression of genes controlling the acquisition of
the osteoblast phenotype [255, 286]. Runx2 is a member of the
Runx family of transcription factors abundantly expressed in cal-
cified cartilage and bone, and it is considered as a master regula-
tory switch essential for osteoblast differentiation [287]. Runx2
may be expressed in early osteoprogenitors, but is also required
for osteoblast function beyond differentiation. Targeted disruption
of Runx2 results in the complete inhibition of bone formation,
revealing that Runx2 is essential for both endochondral and
Table 3 Families of MAPKs
Family Name Function
Extracellular signal-
regulated kinases
ERK1, ERK2
The ERKs (also known as classical MAPK) signalling pathways are activated in
response to GFs, and regulate cell proliferation and cell differentiation
ERK5 (MAPK7) Activated both by GFs and by stress stimuli; participates in cell proliferation
ERK3 (MAPK6) 
ERK4 (MAPK4)
Atypical MAPKs. ERK3/4 are mostly cytoplasmic proteins which bind, 
translocate and activate the MK5 (PRAK, MAP2K5). ERK3 is known as an
unstable unlike ERK4 which is relatively stable
ERK7/8 (MAPK15) New members of MAPKs structurally related to ERK3/4
c-Jun N-terminal kinases (JNKs) MAPK8, MAPK9, MAPK10 Stress-activated protein kinases
p38 isoforms
MAPK11, MAPK12 (ERK6),
MAPK13, MAPK14
Both JNK and p38 signalling pathways are responsive to stress stimuli, such as
cytokines, ultraviolet irradiation, heat shock and osmotic shock, and are
involved in cell differentiation and apoptosis
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intramembranous bone formation. Runx2 acts in nuclear microen-
vironments as a scaffolding protein that controls gene expression
in response to physiological signals. Many transcription factors
interact with Runx2: some provide costimulatory signals, whereas
others repress Runx2 function by affecting its DNA binding activ-
ity and/or transactivation potential [255]. The second transcrip-
tional regulator for the final stages of bone tissue formation is the
human homologue of the mouse Osx i.e. specificity protein-7. This
is a zinc finger transcription factor which contains specific
domains responsible for the activation of OC and Col1a1 genes.
Osx-null osteoblast precursors in the periosteum of membranous
bones express chondrocyte markers, such as Sox9 and Col2a1.
This suggests that Runx2-expressing preosteoblasts are still bipo-
tential cells. Nevertheless, Osx-null osteoblast precursors cannot
differentiate into osteoblasts and deposit bone matrix, so that
endochondral or intramembranous bone formation do not occur
[95]. These data prove that Osx acts downstream of Runx2 to
induce osteoblastic differentiation in osteochondroprogenitor
cells. Osx may be induced by additional signalling pathways act-
ing in parallel to, or independent of, Runx2. It has been shown that
Runx2 is required but not sufficient for the BMP-2-mediated Osx
induction, because MAPK signalling pathways serve as points of
convergence to mediate the BMP-2 effect on Osx expression.
Cooperation between Osx and nuclear factor of activated T cells
activates the Col1a1 and OC promoters and accelerates osteoblast
differentiation and bone formation in a Runx2-independent man-
ner [288]. Another important transcription factor controlling
osteoblast differentiation is ATF4 (activating transcription factor 4)
or cAMP response elements binding protein 2. ATF4 is required
for terminal differentiation of osteoblasts, and it interacts with
Runx2 to regulate bone sialoprotein and OC expression. The cru-
cial role of ATF4 has been shown by blocking its activity and
obtaining a severe decrease in bone formation [289].
Conclusion
The sequential phases of osteoblast commitment and differentiation
are regulated by a variety of complex activities, including hormones,
GF, mechanical stimuli, cell–cell and cell–matrix interaction, that act
via interconnected signalling networks, resulting in the activation of
specific transcription factors and, in turn, their target genes.
Summary
Indirect fracture healing is usually clinically uncomplicated, is
based on endochondral ossification, and proceeds by stages from
haematoma through inflammation, angiogenesis, chondrogenesis
and osteogenesis, to bone remodelling. Non-union, delayed union
and various congenital or acquired bone defects can cause prob-
lems. Instead of traditional internal or external fracture fixation or
osteosynthetic devices, regenerative medicine attempts to recruit,
guide endogenous or to implant various exogenous mesenchymal
or foetal stem cells to support active healing or to replace missing
bone. These attempts often include composites of biodegradable
polymers, e.g. PCL, poly(propylene fumarate) or PLA, with silica,
HA or other calcium phosphate filler particles. Scaffold/matrix-cell
interactions will be better utilized once the biological effects of
aging, hormonal, intracrine, transcriptional and the legal regula-
tion of adult and foetal stem cells are more clearly understood.
PRP provides an inexpensive autologous source of potent biofac-
tors, which together with other signals contribute to osteogenesis
via TGF-, FGF, IGF, PDGF, MAPK, Wnt, hedgehog, Notch and
ephrin signalling via transcriptional regulation, which also provide
the tools to monitor regeneration and healing.
The European Science Foundation was established in 1974 to
create a common European platform for cross-border cooperation
in all aspects of scientific research. With its emphasis on a multidis-
ciplinary and pan-European approach, the Foundation provides the
leadership necessary to open new frontiers in European science.
Today the frontiers of regenerative medicine are rapidly expanding.
Regenerative medicine has already provided new insight into cellu-
lar proliferation, effects of humoural and matrix signalling on cells,
angiogenesis and tissue remodelling as well as basic insights into
cell biology. Nevertheless, regenerative medicine is in its infancy
and to facilitate the process of growth, 14 EU countries funded by
European Science Foundation have joined forces in an attempt to
improve networking and clarify where the frontiers and future needs
are in this complex multidisciplinary field. Proof of principle experi-
ments and randomized clinical trials remain in the future for regen-
erative medicine. In the most visionary view, scientists hope to see
the human body undergo repeated and well timed maintenance of
failing body parts through cycles of healing cell therapies.
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